Use of the HCV subgenomic replicon for the selection and characterization of variants with reduced susceptibility to interferon alpha-2A
β Scribed by C. Laxton; E. Hobbs; S. Fletcher; J.A Symons; R. Bartenschlager; M. Graves; R. Devos; I. Najera
- Book ID
- 119526874
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- English
- Weight
- 166 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Combination treatment with pegylated-interferon-alpha (PEG IFN-β£) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may
## Abstract The use of two new assays was evaluated for predicting the response to interferon (IFN) therapy in patients with chronic hepatitis C. The genotype of hepatitis C virus (HCV) was establishe by an enzymeβlinked immunosorbent assay based on genotypeβspecific recombinant peptides of the NS4